id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1996-P-0031-0003,FDA,FDA-1996-P-0031,"NAPM, National Assn of Pharmaceutical Mf - Citizen Petition",Other,CP-Citizen Petition,2009-01-30T05:00:00Z,2009,1,2009-01-30T05:00:00Z,,2009-01-30T16:18:52Z,,0,0,09000064804fc3f5
FDA-1996-P-0031-0029,FDA,FDA-1996-P-0031,"HFD-1 to Kleinfeld, Kaplan & Becker - Petition Denial",Other,PDN-Petition Denial,2009-01-30T05:00:00Z,2009,1,2009-01-30T05:00:00Z,,2009-01-30T22:02:14Z,,0,0,09000064804fc446
FDA-1996-P-0031-0004,FDA,FDA-1996-P-0031,HFD-1 - Letter,Other,LET-Letter,2009-01-30T05:00:00Z,2009,1,2009-01-30T05:00:00Z,,2009-01-30T16:18:53Z,,0,0,09000064804fc3f8
FDA-1996-P-0031-0023,FDA,FDA-1996-P-0031,"Attachment 4 - ""Disease and Oral Dosage Form Performance"" - [Hoechst Marion Rousell, Inc. - Comment]",Supporting & Related Material,C-Comment (Supporting and Related Material),2009-01-30T05:00:00Z,2009,1,,,2009-01-30T20:51:06Z,,0,0,09000064804fc436
FDA-1996-P-0031-0001,FDA,FDA-1996-P-0031,FDA,Notice,N-Notice,1997-04-07T04:00:00Z,1997,4,1997-04-07T04:00:00Z,1997-06-27T03:59:59Z,2008-05-16T22:20:07Z,,0,0,09000064804fc3de
FDA-1996-P-0031-0002,FDA,FDA-1996-P-0031,HFA-305 to National Assn. of Pharmaceutical Manufacturers,Other,ACK-Acknowledgement Letter,1996-09-05T04:00:00Z,1996,9,,,2008-05-16T22:20:07Z,,0,0,09000064804fc448